Resource

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock, J; Rood, J; Cobitz, A; Biswas, N; Chou, H; Garber, A
Diabetes, obesity & metabolism; 2006 Nov;8(6):650-60. PMID: 17026489
Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA. juliorosenstock@dallasdiabetes.com
Category: 
General Reviews
Links: 
PubMed Article
Journal Article

Abstract

This study assessed the efficacy and safety of rosiglitazone and metformin (RSG/MET) fixed-dose combination (AVANDAMET) as initial therapy in patients with uncontrolled type 2 diabetes compared with monotherapy with either RSG or MET after 32 weeks of treatment.